Diandydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix

S. E. Vogl, V. Seltzer, Fernando J. Camacho, A. Calanog

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eighteen evaluable patients with squamous cancer of the uterine cervix recurrent after radiation therapy or with distant metastases were treated with dianhydrogalactitol (150 mg/m2) and cisplatin (DDP) (50 mg/m2), both given iv every 3 weeks. Only 39% of the patients responded, a result no better than that previously reported for DDP alone and only one-half as good as that previously reported by our group for a combination of this drug with mitomycin, vincristine, and bleomycin. Responses lasted a median of only 5 months. Hematologic toxicity was life-threatening in 22% of the patients and was severe in all but 11% of the remaining patients. We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone.

Original languageEnglish (US)
Pages (from-to)1809-1812
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number10
StatePublished - Jan 1 1982

Fingerprint

Uterine Cervical Neoplasms
Cisplatin
Dianhydrogalactitol
Poisons
Bleomycin
Mitomycin
Vincristine
Drug Combinations
Radiotherapy
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diandydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix. / Vogl, S. E.; Seltzer, V.; Camacho, Fernando J.; Calanog, A.

In: Cancer Treatment Reports, Vol. 66, No. 10, 01.01.1982, p. 1809-1812.

Research output: Contribution to journalArticle

@article{d3466db33a284d4c9e6db730298e51b6,
title = "Diandydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix",
abstract = "Eighteen evaluable patients with squamous cancer of the uterine cervix recurrent after radiation therapy or with distant metastases were treated with dianhydrogalactitol (150 mg/m2) and cisplatin (DDP) (50 mg/m2), both given iv every 3 weeks. Only 39{\%} of the patients responded, a result no better than that previously reported for DDP alone and only one-half as good as that previously reported by our group for a combination of this drug with mitomycin, vincristine, and bleomycin. Responses lasted a median of only 5 months. Hematologic toxicity was life-threatening in 22{\%} of the patients and was severe in all but 11{\%} of the remaining patients. We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone.",
author = "Vogl, {S. E.} and V. Seltzer and Camacho, {Fernando J.} and A. Calanog",
year = "1982",
month = "1",
day = "1",
language = "English (US)",
volume = "66",
pages = "1809--1812",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Diandydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix

AU - Vogl, S. E.

AU - Seltzer, V.

AU - Camacho, Fernando J.

AU - Calanog, A.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Eighteen evaluable patients with squamous cancer of the uterine cervix recurrent after radiation therapy or with distant metastases were treated with dianhydrogalactitol (150 mg/m2) and cisplatin (DDP) (50 mg/m2), both given iv every 3 weeks. Only 39% of the patients responded, a result no better than that previously reported for DDP alone and only one-half as good as that previously reported by our group for a combination of this drug with mitomycin, vincristine, and bleomycin. Responses lasted a median of only 5 months. Hematologic toxicity was life-threatening in 22% of the patients and was severe in all but 11% of the remaining patients. We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone.

AB - Eighteen evaluable patients with squamous cancer of the uterine cervix recurrent after radiation therapy or with distant metastases were treated with dianhydrogalactitol (150 mg/m2) and cisplatin (DDP) (50 mg/m2), both given iv every 3 weeks. Only 39% of the patients responded, a result no better than that previously reported for DDP alone and only one-half as good as that previously reported by our group for a combination of this drug with mitomycin, vincristine, and bleomycin. Responses lasted a median of only 5 months. Hematologic toxicity was life-threatening in 22% of the patients and was severe in all but 11% of the remaining patients. We conclude that the addition of substantial and toxic doses of dianhydrogalactitol to DDP failed to substantially enhance the rate, quality, or duration of response compared to DDP alone.

UR - http://www.scopus.com/inward/record.url?scp=0020000440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020000440&partnerID=8YFLogxK

M3 - Article

C2 - 6889913

AN - SCOPUS:0020000440

VL - 66

SP - 1809

EP - 1812

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -